Powered for progress
and breakthrough.

STAR0602 is Marengo’s first T cell activator generated from Marengo’s STAR platform that provides a ‘dual boost’ to elevate T cell function and response to tumors. STAR0602 acts on a broad range of tumor antigen-specific Vβ 6/10 T cells, which are prevalent across many common cancer types (approximately 10-12% of TILs in each common cancer). By combining a novel non-clonal mode of TCR activation with a T cell co-stimulator delivered to the same T cells, it promotes the expansion of a new population of clonally diverse, effector memory Vβ 6/10 T cells that turbo-charges the anti-tumor immune response and promotes durable clearance of cancer cells. STAR0602 has undergone extensive preclinical testing, which demonstrates potent anti-tumor activity in both mouse and human ex vivo tumor models attributed to a distinct mechanism of action from existing cancer immunotherapies.